Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile

Am J Cardiol. 2002 Sep 15;90(6):628-30. doi: 10.1016/s0002-9149(02)02568-7.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Abciximab
  • Aged
  • Angioplasty, Balloon, Coronary*
  • Antibodies, Monoclonal / therapeutic use*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / therapy*
  • Double-Blind Method
  • Endpoint Determination
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Predictive Value of Tests
  • Risk Factors
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab